Summary:Case reportA 38-year-old man (blood group A+; phenotype A 38-year-old man, blood group A+, was allotransplanted for multiple myeloma from his fully matched D+C+E−c+e+K−) was allotransplanted for multiple myeloma from his fully HLA-matched sister (blood group O+, sister, blood group O+. Anti-A antibodies IgG and IgM titres of the donor were low. Allogeneic peripheral blood phenotype D+C−E−c+e+K−). Recipient and donor ABO groups were determined twice using RBC grouping test and stem cells were harvested by leukapheresis after subcutaneous administration of G-CSF. Rapid serum grouping test. No unexpected alloantibody was identified. Anti-A antibodies IgG and IgM titres of the engraftment occurred since 5.6 × 10 9 /l leukocytes were achieved on day +9 post-transplant. At this time a sevdonor were low (both 1/8). Allogeneic peripheral blood stem cells were harvested by leukapheresis after subcutaneere immune haemolytic syndrome occurred and direct antiglobulin test was positive (IgG and C3d). Elution ous administration of G-CSF (granocyte, kindly provided by Bellon, Neuilly, France) (CD34 + 3.5 × 10 6 /kg; CD3 + showed an anti-A specificity. Evolution was rapidly unfavourable related to multiorgan failure. The patient 410 × 10 6 /kg; CD19 + 79 × 10 6 /kg). The conditioning regimen consisted of cyclophosphamide (60 mg/kg) and TBI; died on day +20 post-transplant. Keywords: ABO incompatibility; allogeneic peripheral prevention of GVHD was provided by cyclosporin A (CsA) and methylprednisolone. No deplasmatisation of the blood stem cell transplantation APBSC was performed since anti-A antibody titre of the donor was low. Rapid engraftment occurred since 500/mm 3 and 5600/mm 3 leukocytes were achieved on day +8 and +9, Allogeneic bone marrow transplantation can be successrespectively. Two transfusions of phenotyped and irradiated fully performed despite ABO incompatibility between the A+ RBC and one irradiated platelet transfusion of group donor and recipient. Major incompatibility may cause a A+ were given to the patient on day +7 when Hb was severe haemolytic transfusion reaction at the time of BMT 7.1 g/dl and platelet counts were 6000/mm 3 . On day +9, a due to interaction of donor type RBC with pre-existing severe immune haemolytic syndrome occurred: acute anehost-derived isohaemagglutins. This complication can be mia, backpain, elevation of bilirubin, LDH and serum prevented easily by removing RBC from the marrow graft.creatinin. Direct antiglobulin test was positive (IgG and On the other hand minor incompatibility, where donorC3d) (Figure 1). Serum testing showed the presence of antiderived antibodies are directed against ABO antigens of the A alloantibodies. The saline indirect antiglobulin test recipient erythrocytes, may lead to delayed immune haeshowed an anti-A specificity and elution in LISS (low ionic molysis caused by transient antibody production from strength saline) solution revealed strong reactivity anti-A donor immunocompetent lymphocytes. This complication (++++). Group O RBC with original r...

Background: Malnutrition is a critical predictor of toxicity and outcome in patients with cancer and may be perceived differently by patients, relatives, and physicians. Aims: To assess the prevalence of malnutrition in oncology departments and to compare it with the perceptions of nutrition status by patients themselves, their closest relatives, and attending physicians. Materials and Methods: A 1-day multicentric cross-sectional survey on the prevalence of malnutrition was conducted in different oncology departments using patient-, relative-, and physician-specific questionnaires. Malnutrition was defined by a weight loss ࣙ5% within 1 month or ࣙ10% within 6 months, a body mass index ࣘ18.5 kg/m 2 in patients aged <70 years or ࣘ21 kg/m 2 in patients aged ࣙ70 years, and/or albuminemia <35 g/L. Questionnaires for assessing medical condition, knowledge of nutrition status, and perceptions of the impact of malnutrition on daily life were distributed to consenting patients, attending physicians, and closest relatives. Results: A total of 2197 patients were included, and 2071 and 976 questionnaires were collected from patients and relatives, respectively. Prevalence of malnutrition was 39%. Physicians overestimated malnutrition (44%), whereas patients and relatives underestimated it (22% and 23%, respectively, P < .001). Conversely, malnutrition-associated symptoms were underestimated by physicians compared with patients and relatives. Conclusion: We found a prevalence of malnutrition of 39%: it was underestimated by patients and relatives and overestimated by physicians. (JPEN J Parenter Enteral Nutr. 2018;42:255-260)

The prognosis of metastatic pancreatic ductal adenocarcinoma (PDAC) is grim, with a median overall survival of under 1 year. In our clinical practice, we observed a few cases of isolated lung metastases from PDAC with unusually long outcomes. We compared these cases in a case-control study of lung-only vs. liver-only metastases from PDAC.From our database, we found 37 cases of lung-only metastases and paired them with 37 cases of liver-only metastases by age, tumor location and treatment.The lung-only group differed significantly from the liver-only group with respect to the following parameters: female predominance, more metachronous cases, fewer nodules per patient, and smaller increases in tumor markers. Local invasion parameters (i.e., arterial or venous involvement) were not significantly different. The outcomes were significantly different, with a median overall survival from the occurrence of metastases of 20.8 vs. 9.1 months and a median progression-free survival of 11 vs. 3.5 months.In conclusion, this case-control study seemed to confirm that lung-only PDAC metastases have prognoses different from those of liver-only metastases. A better understanding of the mechanisms underlying these differences will help identify abnormalities associated with tumor aggressiveness.

Pancreatoblastomas are unfrequent tumors usually found in children. We report two cases of metastatic pancreatoblastomas observed in young women. A systemic chemotherapy (FOLFIRINOX regimen) was associated with a disease control in one case and a partial response in the second with an improvement of general status for both. A high-throughput sequencing of the tumor described in both cases alteration in the Wnt/β-catenin pathway: a mutation in CTNNB1 (exon 3, c.110C&gt;G, p.S37C, reported as a hotspot in COSMIC) in one case and a homozygous loss associated with breakage targeting APC (5q22.2) in the second.

Tumoral angiogenesis appears to be an independent prognostic factor for node-positive breast cancer, when treated with adjuvant chemotherapy. Adjuvant strategies for patients with a high level of angiogenesis should be discussed.